Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients
Launched by MUHAMMAD AAMIR LATIF · Mar 15, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
Given the significant burden of transfusion dependency, an effective and safe inducer is needed that could improve quality of life and reduce the healthcare costs associated with frequent transfusions and iron chelation therapy. If this study could establish the safety of thalidomide in terms of teratogenicity along with its efficacy, it would be a great support to multi-transfused thalassemic children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children of both genders
- • Aged 2-5 years
- • With transfusion-dependent thalassemia (TDT)
- • Whose parents/guardians showed willingness to adhere to follow-up visits
- Exclusion Criteria:
- • Children with uncontrolled infections
- • Significant hepatic or renal dysfunction
- • Malignancy
- • Known contraindications to thalidomide
About Muhammad Aamir Latif
Muhammad Aamir Latif is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical research and a focus on innovative therapeutic solutions, he collaborates with healthcare professionals and institutions to design, implement, and oversee clinical trials. His expertise encompasses various therapeutic areas, ensuring adherence to regulatory standards and ethical guidelines. Through strategic partnerships and a patient-centered approach, Muhammad Aamir Latif aims to contribute significantly to the development of safe and effective treatments, fostering advancements in healthcare and enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multan, Punjab, Pakistan
Patients applied
Trial Officials
Muhammad Aslam, FCPS
Principal Investigator
Children's Hospital and institute of Child Health Multan, Punjab, Pakistan
Sara Rubab, FCPS
Principal Investigator
Children's Hospital and institute of Child Health Multan, Punjab, Pakistan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported